Hims & Hers Health

7 members

What's driving coverage of Hims & Hers Health right now?

Corporate ratings

Medium Risk

hims & hers received a Medium Risk rating largely because of its funding practices and willingness to engage in politically charged advocacy and governance decisions. While the company shows lower risk in areas like cancellations and political actions, its tendency to let activism influence corporate policy pulls its overall score toward moderate risk.

CancellationsLower Risk
Discriminatory PhilanthropyNot rated
Employment ProtectionMedium Risk
Corporate WeaponizationNot rated
Advocacy BiasMedium Risk
FundingHigh Risk
Political ActionsLower Risk

7 memberscoverage spread: L0/C100/R0

Comments

Ask this entity anything:

Free account · your comment posts right after signup

Health
FDA panel backs BPC-157 access, Hims shares surge
An FDA advisory panel recommended adding BPC-157 to the list eligible for pharmacy compounding, a move investors interpreted as a boost to Hims & Hers' telehealth and peptide offerings, with the stock jumping about 10–11% across reports. The company, valued around $8.1 billion, has faced insider selling in the past quarter, and regulators’ signaling comes as it positions itself in a growing peptide therapy market.
9 sources

Hims & Hers Health

Corporate ratings

Comments

FDA panel backs BPC-157 access, Hims shares surge

Hims & Hers Health

Overview

Corporate ratings

Comments

FDA panel backs BPC-157 access, Hims shares surge

Hims & Hers Health across IJR

Overview

Hims & Hers Health across IJR